Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 209, Issue 7, Pages 1325-1334Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20101974
Keywords
-
Categories
Funding
- Department of Neurology and Neurological Sciences
- National Institutes of Health
- National Multiple Sclerosis Society
- John and Sally Endiz
- Guthy-Jackson Charitable Foundation
Ask authors/readers for more resources
Comparison of transcriptomic and proteomic data from pathologically similar multiple sclerosis (MS) lesions reveals down-regulation of CD47 at the messenger RNA level and low abundance at the protein level. Immunohistochemical studies demonstrate that CD47 is expressed in normal myelin and in foamy macrophages and reactive astrocytes within active MS lesions. We demonstrate that CD47(-/-) mice are refractory to experimental autoimmune encephalomyelitis (EAE), primarily as the result of failure of immune cell activation after immunization with myelin antigen. In contrast, blocking with a monoclonal antibody against CD47 in mice at the peak of paralysis worsens EAE severity and enhances immune activation in the peripheral immune system. In vitro assays demonstrate that blocking CD47 also promotes phagocytosis of myelin and that this effect is dependent on signal regulatory protein. (SIRP-alpha). Immune regulation and phagocytosis are mechanisms for CD47 signaling in autoimmune neuroinflammation. Depending on the cell type, location, and disease stage, CD47 has Janus-like roles, with opposing effects on EAE pathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available